Morphogen Delivery by Osteoconductive Nanoparticles Instructs Stromal Cell Spheroid Phenotype

Jacklyn Whitehead, Alefia Kothambawala, J. Kent Leach

Research output: Contribution to journalArticle

Abstract

Mesenchymal stem/stromal cells (MSCs) exhibit a rapid loss in osteogenic phenotype upon removal of osteoinductive cues, as commonly occurs during transplantation. Osteogenic differentiation can be more effectively but not fully maintained by aggregating MSCs into spheroids. Therefore, the development of effective strategies that prolong the efficacy of inductive growth factors would be advantageous for advancing cell-based therapies. To address this challenge, osteoinductive bone morphogenetic protein-2 (BMP-2) is adsorbed to osteoconductive hydroxyapatite (HA) nanoparticles for incorporation into MSC spheroids. MSC induction is evaluated in osteogenic conditions and retention of the osteogenic phenotype in the absence of other osteogenic cues. HA is more uniformly incorporated into spheroids at lower concentrations, while BMP-2 dosage is dependent upon initial morphogen concentration. MSC spheroids containing BMP-2-loaded HA nanoparticles exhibit greater alkaline phosphatase activity and more uniform spatial expression of osteocalcin compared to spheroids with uncoated HA nanoparticles. Spheroids cultured in media containing soluble BMP-2 demonstrate differentiation only at the spheroid periphery. Furthermore, the osteogenic phenotype of MSC spheroids is better retained with BMP-2-laden HA upon the removal of soluble osteogenic cues. These findings represent a promising strategy for simultaneous delivery of osteoconductive and osteoinductive signals for enhancing MSC participation in bone formation.

Original languageEnglish (US)
Article number1900141
JournalAdvanced Biosystems
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Stromal Cells
Stem cells
Mesenchymal Stromal Cells
Nanoparticles
Bone Morphogenetic Protein 2
Durapatite
Hydroxyapatite
Bone
Phenotype
Proteins
Cues
Osteocalcin
Phosphatases
Alkaline Phosphatase
Intercellular Signaling Peptides and Proteins
Cell- and Tissue-Based Therapy
Osteogenesis
Transplantation

Keywords

  • bone morphogenetic protein-2
  • hydroxyapatite
  • mesenchymal stem/stromal cells
  • osteogenesis
  • spheroids

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Morphogen Delivery by Osteoconductive Nanoparticles Instructs Stromal Cell Spheroid Phenotype. / Whitehead, Jacklyn; Kothambawala, Alefia; Kent Leach, J.

In: Advanced Biosystems, 01.01.2019.

Research output: Contribution to journalArticle

@article{1b6f5733079442e6b1d6869f4983849e,
title = "Morphogen Delivery by Osteoconductive Nanoparticles Instructs Stromal Cell Spheroid Phenotype",
abstract = "Mesenchymal stem/stromal cells (MSCs) exhibit a rapid loss in osteogenic phenotype upon removal of osteoinductive cues, as commonly occurs during transplantation. Osteogenic differentiation can be more effectively but not fully maintained by aggregating MSCs into spheroids. Therefore, the development of effective strategies that prolong the efficacy of inductive growth factors would be advantageous for advancing cell-based therapies. To address this challenge, osteoinductive bone morphogenetic protein-2 (BMP-2) is adsorbed to osteoconductive hydroxyapatite (HA) nanoparticles for incorporation into MSC spheroids. MSC induction is evaluated in osteogenic conditions and retention of the osteogenic phenotype in the absence of other osteogenic cues. HA is more uniformly incorporated into spheroids at lower concentrations, while BMP-2 dosage is dependent upon initial morphogen concentration. MSC spheroids containing BMP-2-loaded HA nanoparticles exhibit greater alkaline phosphatase activity and more uniform spatial expression of osteocalcin compared to spheroids with uncoated HA nanoparticles. Spheroids cultured in media containing soluble BMP-2 demonstrate differentiation only at the spheroid periphery. Furthermore, the osteogenic phenotype of MSC spheroids is better retained with BMP-2-laden HA upon the removal of soluble osteogenic cues. These findings represent a promising strategy for simultaneous delivery of osteoconductive and osteoinductive signals for enhancing MSC participation in bone formation.",
keywords = "bone morphogenetic protein-2, hydroxyapatite, mesenchymal stem/stromal cells, osteogenesis, spheroids",
author = "Jacklyn Whitehead and Alefia Kothambawala and {Kent Leach}, J.",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/adbi.201900141",
language = "English (US)",
journal = "Advanced Biosystems",
issn = "2366-7478",
publisher = "Wiley-VCH Verlag",

}

TY - JOUR

T1 - Morphogen Delivery by Osteoconductive Nanoparticles Instructs Stromal Cell Spheroid Phenotype

AU - Whitehead, Jacklyn

AU - Kothambawala, Alefia

AU - Kent Leach, J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Mesenchymal stem/stromal cells (MSCs) exhibit a rapid loss in osteogenic phenotype upon removal of osteoinductive cues, as commonly occurs during transplantation. Osteogenic differentiation can be more effectively but not fully maintained by aggregating MSCs into spheroids. Therefore, the development of effective strategies that prolong the efficacy of inductive growth factors would be advantageous for advancing cell-based therapies. To address this challenge, osteoinductive bone morphogenetic protein-2 (BMP-2) is adsorbed to osteoconductive hydroxyapatite (HA) nanoparticles for incorporation into MSC spheroids. MSC induction is evaluated in osteogenic conditions and retention of the osteogenic phenotype in the absence of other osteogenic cues. HA is more uniformly incorporated into spheroids at lower concentrations, while BMP-2 dosage is dependent upon initial morphogen concentration. MSC spheroids containing BMP-2-loaded HA nanoparticles exhibit greater alkaline phosphatase activity and more uniform spatial expression of osteocalcin compared to spheroids with uncoated HA nanoparticles. Spheroids cultured in media containing soluble BMP-2 demonstrate differentiation only at the spheroid periphery. Furthermore, the osteogenic phenotype of MSC spheroids is better retained with BMP-2-laden HA upon the removal of soluble osteogenic cues. These findings represent a promising strategy for simultaneous delivery of osteoconductive and osteoinductive signals for enhancing MSC participation in bone formation.

AB - Mesenchymal stem/stromal cells (MSCs) exhibit a rapid loss in osteogenic phenotype upon removal of osteoinductive cues, as commonly occurs during transplantation. Osteogenic differentiation can be more effectively but not fully maintained by aggregating MSCs into spheroids. Therefore, the development of effective strategies that prolong the efficacy of inductive growth factors would be advantageous for advancing cell-based therapies. To address this challenge, osteoinductive bone morphogenetic protein-2 (BMP-2) is adsorbed to osteoconductive hydroxyapatite (HA) nanoparticles for incorporation into MSC spheroids. MSC induction is evaluated in osteogenic conditions and retention of the osteogenic phenotype in the absence of other osteogenic cues. HA is more uniformly incorporated into spheroids at lower concentrations, while BMP-2 dosage is dependent upon initial morphogen concentration. MSC spheroids containing BMP-2-loaded HA nanoparticles exhibit greater alkaline phosphatase activity and more uniform spatial expression of osteocalcin compared to spheroids with uncoated HA nanoparticles. Spheroids cultured in media containing soluble BMP-2 demonstrate differentiation only at the spheroid periphery. Furthermore, the osteogenic phenotype of MSC spheroids is better retained with BMP-2-laden HA upon the removal of soluble osteogenic cues. These findings represent a promising strategy for simultaneous delivery of osteoconductive and osteoinductive signals for enhancing MSC participation in bone formation.

KW - bone morphogenetic protein-2

KW - hydroxyapatite

KW - mesenchymal stem/stromal cells

KW - osteogenesis

KW - spheroids

UR - http://www.scopus.com/inward/record.url?scp=85073987398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073987398&partnerID=8YFLogxK

U2 - 10.1002/adbi.201900141

DO - 10.1002/adbi.201900141

M3 - Article

AN - SCOPUS:85073987398

JO - Advanced Biosystems

JF - Advanced Biosystems

SN - 2366-7478

M1 - 1900141

ER -